A detailed history of United Capital Financial Advisers, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, United Capital Financial Advisers, LLC holds 10,372 shares of VRTX stock, worth $5.21 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
10,372
Previous 10,221 1.48%
Holding current value
$5.21 Million
Previous $4.27 Million 13.79%
% of portfolio
0.04%
Previous 0.04%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $59,314 - $73,315
151 Added 1.48%
10,372 $4.86 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $81,130 - $88,769
199 Added 1.99%
10,221 $4.27 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $492,891 - $590,147
1,437 Added 16.74%
10,022 $4.08 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $62,563 - $67,055
-185 Reduced 2.11%
8,585 $2.99 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $47,791 - $53,490
-152 Reduced 1.7%
8,770 $3.09 Million
Q1 2023

Aug 14, 2023

BUY
$283.23 - $323.1 $43,050 - $49,111
152 Added 1.73%
8,922 $2.81 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $282,663 - $322,453
-998 Reduced 10.06%
8,922 $2.81 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $60,295 - $67,832
-211 Reduced 2.08%
9,920 $2.86 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $1.49 Million - $1.66 Million
5,446 Added 116.24%
10,131 $2.93 Million
Q2 2022

Aug 11, 2022

BUY
$234.96 - $292.55 $808,027 - $1.01 Million
3,439 Added 276.0%
4,685 $1.32 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $56,683 - $66,808
-256 Reduced 17.04%
1,246 $325,000
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $8,496 - $10,725
48 Added 3.3%
1,502 $330,000
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $103,392 - $115,704
-570 Reduced 28.16%
1,454 $264,000
Q2 2021

Aug 13, 2021

SELL
$187.49 - $221.1 $69,558 - $82,028
-371 Reduced 15.49%
2,024 $408,000
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $132,492 - $154,438
-640 Reduced 21.09%
2,395 $515,000
Q4 2020

Feb 17, 2021

SELL
$207.01 - $276.09 $4.4 Million - $5.87 Million
-21,264 Reduced 87.51%
3,035 $717,000
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $25,053 - $29,703
-98 Reduced 0.4%
24,299 $6.61 Million
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $867,196 - $1.14 Million
3,846 Added 18.71%
24,397 $7.08 Million
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $569,943 - $707,001
-2,853 Reduced 12.19%
20,551 $4.89 Million
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $64,016 - $85,981
384 Added 1.67%
23,404 $5.12 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $132,152 - $148,736
795 Added 3.58%
23,020 $3.9 Million
Q2 2019

Aug 13, 2019

BUY
$164.61 - $190.37 $436,710 - $505,051
2,653 Added 13.56%
22,225 $4.08 Million
Q1 2019

May 14, 2019

BUY
$163.73 - $194.7 $398,682 - $474,094
2,435 Added 14.21%
19,572 $3.6 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $372,027 - $470,722
2,449 Added 16.67%
17,137 $2.84 Million
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $494,635 - $568,390
2,949 Added 25.12%
14,688 $2.83 Million
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $363,571 - $424,050
2,495 Added 26.99%
11,739 $2 Million
Q1 2018

May 15, 2018

SELL
$151.6 - $177.13 $543,637 - $635,188
-3,586 Reduced 27.95%
9,244 $1.51 Million
Q4 2017

Feb 13, 2018

BUY
$137.28 - $155.55 $151,145 - $171,260
1,101 Added 9.39%
12,830 $1.92 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $982,546 - $1.08 Million
6,633 Added 130.16%
11,729 $1.78 Million
Q2 2017

Aug 14, 2017

BUY
N/A
5,096
5,096 $657,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track United Capital Financial Advisers, LLC Portfolio

Follow United Capital Financial Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on United Capital Financial Advisers, LLC with notifications on news.